focus -WSS

focus

author：entertainment 2025-10-02 02:34:56 - browse：743

What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for a biotech blow-up?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.

For more on what we cover, here’s the radiopharmaceuticals story; here’s the news on Lilly; here’s more on Ventyx Biosciences; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ionis has late

entertainment

WSS

Covid vaccines: Private market messier than government rollout

Intercept Pharmaceuticals sells itself for less than $1 billion

Mindstrong's demise and the future of mental health care

WHO recommends dropping component of many flu vaccines

Medicare drug price negotiation program allowed for now

Kaiser Permanente unions announce official strike date

knowledge

focus

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Mindstrong's demise and the future of mental health care

23andMe had bad news about my health. I wish a person had delivered it

Researchers use wearables data and AI to predict preterm birth risk

Virginia high school admissions case could be legal follow

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

New air purifier tech could be key to improving indoor air quality

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Medicare details structure of new drug price negotiation program

How one patient went off dialysis — and others can too

explore

Listen: Who gets the credit for GLP

NIH study of ME/CFS points to clear biological hallmarks

In utero gene editing: an explainer

Menendez indictment could see pharma lose a key ally

Kaiser Permanente unions announce official strike date

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

focus

entertainment

focus

knowledge